Patents by Inventor Yangbing Zhao

Yangbing Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210216148
    Abstract: A display device, an electronic device, and a method for driving a display device are provided. The display device includes a display panel and a plurality of image sensors. The display panel has a display side and a back side opposite to the display side, the plurality of image sensors are independent at a plurality of independent positions on the back side of the display panel, and the plurality of image sensors are configured to integrally obtain depth image information of a target to be detected on the display side of the display panel.
    Type: Application
    Filed: January 14, 2019
    Publication date: July 15, 2021
    Applicant: BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Pengpeng WANG, Haisheng WANG, Xiaoliang DING, Wenqing ZHAO, Yangbing LI, Yapeng LI, Likai DENG, Yuanyuan MA, Lei WANG
  • Patent number: 11028143
    Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
  • Publication number: 20210155667
    Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 27, 2021
    Inventors: Yangbing Zhao, Xiaojun Liu, Wei Pan
  • Publication number: 20210137980
    Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
    Type: Application
    Filed: March 5, 2020
    Publication date: May 13, 2021
    Inventors: Yangbing Zhao, Szu Hua Sharon Lin, Xiaojun Liu, Anne Chew
  • Patent number: 10981969
    Abstract: The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 20, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao
  • Publication number: 20210069239
    Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a chimeric antigen receptor (CAR) capable of binding human PSCA. CARs capable of binding human PSCA, and nucleic acids encoding the same are also provided. Provided herein are bispecific CARs capable of binding human PSCA and human PSMA, nucleic acids encoding the same, and modified immune cells comprising the same. Modified immune cells comprising a PSMA CAR and a PSCA CAR are also provided. Compositions and methods of treatment are also provided.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 11, 2021
    Inventor: Yangbing Zhao
  • Patent number: 10934336
    Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 2, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Xiaojun Liu, Wei Pan
  • Publication number: 20210040234
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
    Type: Application
    Filed: June 24, 2020
    Publication date: February 11, 2021
    Inventors: Carl H. June, Yangbing Zhao, Xiaojun Liu
  • Publication number: 20210009652
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Application
    Filed: February 17, 2020
    Publication date: January 14, 2021
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • Publication number: 20210008188
    Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 14, 2021
    Inventors: Yangbing Zhao, Carl H. June, Xiaojun Liu
  • Publication number: 20200407728
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Application
    Filed: July 30, 2020
    Publication date: December 31, 2020
    Inventors: Yangbing Zhao, Jiangtao Ren, Xiaojun Liu, Carl H. June
  • Patent number: 10828353
    Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 10, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Carl H. June, Xiaojun Liu
  • Publication number: 20200345778
    Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Yangbing Zhao, Szu Hua Sharon Lin, Xiaojun Liu, Anne Chew
  • Patent number: 10800840
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 13, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Patent number: 10780120
    Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 22, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Szu Hua Sharon Lin, Xiaojun Liu, Anne Chew
  • Publication number: 20200283729
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
    Type: Application
    Filed: October 11, 2019
    Publication date: September 10, 2020
    Inventors: Andreas Loew, Michael C. Milone, Daniel J. Powell, JR., Yangbing Zhao
  • Patent number: 10696749
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 30, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao, Xiaojun Liu
  • Publication number: 20200087659
    Abstract: The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 19, 2020
    Inventors: Carl H. June, Yangbing Zhao
  • Patent number: 10577407
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 3, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • Publication number: 20200054679
    Abstract: The present invention includes compositions and methods for modifying primary T cells. In one aspect, the invention comprises administering to a cell a stem-loop Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (st-crRNA) and a Cpf1 enzyme.
    Type: Application
    Filed: May 2, 2018
    Publication date: February 20, 2020
    Inventors: Yangbing Zhao, Jiangtao Ren